ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Rheum

Long COVID: Experts Weigh in on Increasingly Common Syndrome

Ruth Jessen Hickman, MD  |  March 16, 2023

A minority of patients experience lingering symptoms after infec­tion with SARS-CoV-2, similar to some other previously known post-infection syndromes. Although we are just beginning to understand the differ­ent presen­tations, pathophysiology, risk factors, prognosis and treatment of long COVID, rheumatologists can play a leader­ship role in managing patients with the illness and contributing to this important research…

2022 ACR Guideline for Vaccinations in Patients with RMDs

Arthritis & Rheumatology  |  February 27, 2023

This guideline provides evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases. It includes expanded indications for some vaccines, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity and efficacy.

Rheumatology Research Foundation Supports High-Risk, High-Reward Ideas

Leslie Mertz, PhD  |  February 21, 2023

Now in the second year of his 2021–2023 term as the Rheumatology Research Foundation president, V. Michael Holers, MD, a professor of medicine and immunology and the Smyth Professor of Rheumatology at the University of Colorado, Denver, is looking forward to fortifying and expanding the Foundation’s missions in the framework of its new strategic plan.

ACR Convergence 2022 Closing Session Discusses Research Highlights

Thomas R. Collins  |  February 15, 2023

PHILADELPHIA—Expert panelists gathered in the closing session at ACR Convergence 2022 to give their take on what they saw as some of the most notable research findings and other insights to come out of the meeting, touching on a number of topics on the leading edge of the field. COVID-19 Prophylaxis & Vaccinations Alfred Kim,…

3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA

Arthritis Care & Research  |  February 14, 2023

Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…

RheumMadness 2023: the All-Star Season

David L. Leverenz, MD, MEd  |  February 13, 2023

RheumMadness is back for its third season, and everyone who is crazy about rheumatology is welcome to play. That includes practicing rheumatologists, fellows, residents, medical students, advanced practice providers, other healthcare professionals and patients. Basically, if you are reading this article, you can play RheumMadness. RheumMadness is an online tournament in which a bracket of…

How Long Should Methotrexate Be Held Following Seasonal Vaccinations?

Arthritis & Rheumatology  |  February 1, 2023

Vaccinations against preventable diseases, including seasonal influenza, are strongly recommended for patients with rheumatoid arthritis (RA), who are at increased risk of infections as a result of underlying immune dysfunction and treatment-induced immunosuppression. Park et al. conducted this clinical trial to investigate whether discontinuing methotrexate for one week after seasonal influenza vaccination is noninferior to discontinuing it for two weeks after vaccination in patients with RA.

2023 Medicare Physician Fee Schedule Final Rule for Quality Payment Program Published

From the College  |  January 6, 2023

The ACR highlights essential policy and reporting changes to the Quality Payment Program for performance year 2023 and beyond. Key changes include policies regarding the development of new MIPS Value Pathways and refinement of subgroup participation.

Gout & Excess Risk of Severe SARS-CoV-2 Infection

Arthritis & Rheumatology  |  January 3, 2023

In this large, population-based study, Xie et al. found that the risks of SARS-CoV-2 infection, 30-day hospitalization and 30-day death were higher among individuals with gout than individuals without gout in the general population, irrespective of COVID-19 vaccination status.

Considering Benzbromarone as First-Line Therapy for Gout

Arthritis & Rheumatology  |  December 1, 2022

In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 129
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences